Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio --(BUSINESS WIRE)--Apr.
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-Mini ™ devices in the United States , and EnCompass ®
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial
MASON, Ohio --(BUSINESS WIRE)--Jul. 23, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory
Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio --(BUSINESS WIRE)--May 1, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative
Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year Full Year 2023 International
Worldwide revenue of $98.3 million – an increase of 18.1% year over year U.S. revenue of $81.7 million – an increase of 17.1% year over year International revenue of $16.6 million – an increase of 23.2% year over year Net loss of $9.1 million – an improvement of $3.2 million year over year Positive
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvement of $9.7 million year over year
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Jan. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief
MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms.
